Shots:

• The EMA’s CHMP has adopted a positive opinion recommending the approval of Dupixent as an add-on maintenance treatment in children aged 6 to 11yrs. with sev. asthma. The EC’s decision is expected in the coming mos.
• The opinion was based on the P-III data of Dupixent which showed a reduction in the rate of severe asthma attacks & improved lung function within 2wks. with sustained improvement ~52wks. & the safety results were consistent with the known safety profile of Dupixent in patients aged ≥12yrs. with uncontrolled mod. to sev. asthma
• Dupixent is approved in the EU, US, Japan & other countries globally for certain patients with asthma, specific patients with mod. to sev. AD along with CRSwNP in different age population

Ref: Sanofi | Image: Akarapi Logo